Rabbit Polyclonal CEBPA Antibody

The CEBPA (CCAAT/Enhancer-Binding Protein Alpha) antibody is a crucial tool for studying the CEBPA transcription factor, which belongs to the bZIP family and regulates cellular differentiation, metabolism, and immune responses. CEBPA is particularly vital in hematopoiesis, where it drives granulocytic differentiation and maintains myeloid progenitor cell balance. Dysregulation or mutations in the CEBPA gene are associated with acute myeloid leukemia (AML), making its detection diagnostically and prognostically significant. Antibodies targeting CEBPA enable researchers to assess protein expression levels, localization, and post-translational modifications via techniques like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies often recognize specific epitopes, including N-terminal or C-terminal regions, to distinguish between full-length and truncated isoforms resulting from mutations. In clinical settings, CEBPA antibody-based assays help identify AML patients with biallelic CEBPA mutations, which correlate with favorable outcomes. Beyond oncology, CEBPA antibodies are used to explore its roles in adipogenesis, liver metabolism, and inflammation. Validation of antibody specificity is critical, as cross-reactivity with homologous family members (e.g., CEBPB or CEBPD) can occur. Overall, CEBPA antibodies bridge molecular research and clinical diagnostics, advancing understanding of cellular differentiation mechanisms and therapeutic targeting.